<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01317550</url>
  </required_header>
  <id_info>
    <org_study_id>2010-0872</org_study_id>
    <secondary_id>R01 026582-26</secondary_id>
    <secondary_id>NCI-2011-00778</secondary_id>
    <nct_id>NCT01317550</nct_id>
  </id_info>
  <brief_title>A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil</brief_title>
  <official_title>A Pilot Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to compare armodafinil and minocycline when given
      alone or in combination to learn which is better for controlling symptoms, such as the side
      effects of chemoradiation, when given to treat lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:

      Armodafinil is designed to prevent excessive sleepiness.

      Minocycline is an antibiotic. Minocycline has been shown to interrupt cytokine production,
      which may help to reduce multiple symptoms.

      A placebo is not a drug. It looks like the study drug but is not designed to treat any
      disease or illness. It is designed to be compared with a study drug to learn if the study
      drug has any real effect.

      Study Groups:

      If you agree to take part in this study, you will be randomly assigned (as in the roll of
      dice) to join 1 of 4 groups.

        -  Group 1 will take armodafinil and a placebo.

        -  Group 2 will take minocycline and a placebo.

        -  Group 3 will take armodafinil and minocycline.

        -  Group 4 will take placebos alone.

      Neither you nor the study staff you will see in the clinic will know if you are receiving the
      study drug(s) and/or the placebo(s). However, if needed for your safety, the study staff will
      be able to find out which study drug you are receiving.

      If needed, during this study, you may receive standard care by your treating doctors.

      Study Drug Administration:

      You will take the study drug(s)/placebos every day for 10 weeks. You should take the
      drug(s)/placebo(s) with a full glass of water. If you get an upset stomach, take them with
      food.

      You will be given pamphlets with more information about how to take the study drugs/placebos.

      You should bring your study drug/placebo capsules to the clinic every study visit.

      Completing the Symptom Questionnaire:

      Throughout the study, you will be asked to complete the symptom questionnaire. You will be
      asked about symptoms from therapy you may be experiencing and how they may be interfering
      with your daily activities. The study staff will either meet you during your regular clinic
      visit or call you at your home at a time that is convenient for you. In the clinic, you will
      complete the questionnaire by paper and pen, or by entering your answers into an electronic
      tablet computer. On the phone, study staff will ask you the questions and record your answers
      on paper or enter them into a computer. You will complete the symptom questionnaire before
      you begin chemoradiation and then 1 time a week during Weeks 1-16 of the study. The symptom
      questionnaire will take up to 5 minutes to complete.

      Study Visits:

      Before you begin chemoradiation:

        -  You will complete 4 questionnaires about pain and other symptoms, your mood, and your
           quality of life. Completing all 4 of the questionnaires will take about 15 minutes.

        -  If you are able to become pregnant, you will have a urine pregnancy test. The study
           staff will give you the pregnancy test kit at your scheduled visit, and will review and
           record the results of the test before you can pick up the study drugs from the pharmacy.
           The pregnancy test will be repeated at weeks 1, 4, 7, and 12 (or at the first follow-up
           clinic visit post-treatment) and 30 days after the study drugs are stopped .

      During the last week of chemoradiation (about Week 7):

      -You will complete 3 questionnaires about your symptoms, mood, and quality of life. These
      questionnaires will take about 10 minutes total to complete.

      After about Week 7, the study staff will call you 1 time a week to check on you until Week
      10. This phone call should last only a few minutes. If you have had several side effects from
      chemoradiation, this phone call may take longer.

      About Week 12 (or at the first routine follow-up clinic visit post-treatment):

        -  You will complete the 3 questionnaires about your symptoms, mood, and quality of life.

        -  If you were smoking at the beginning of the study, you will complete a questionnaire
           that asks if you stopped smoking any time during the study. This will take a few minutes
           to complete.

        -  You will be asked to complete another questionnaire that asks about your satisfaction
           with the study drug(s). This will take a few minutes.

      Length of Study:

      You will be on study for about 16 weeks. You will take the study drug(s) for 10 weeks and
      complete the symptom survey until Week 16. You will be taken off study early if you have
      intolerable side effects.

      This is an investigational study. Armodafinil is FDA approved and commercially available for
      the treatment of excessive sleepiness. Minocycline is FDA approved and commercially available
      for the treatment of bacterial infections. The use of these drugs to help reduce
      chemoradiation symptoms is investigational.

      Up to 12 patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Variable: Combined AUC of Selected Symptoms Fatigue, Pain, Disturbed Sleep, Lack of Appetite and Drowsiness</measure>
    <time_frame>During 10 weeks of CXRT</time_frame>
    <description>Each item is rated on a 0 to 10 scale with 0 = symptom not present or no interference and 10 meaning the symptom severity is as bad as can be imagine or complete interference using the MD Anderson Symptom Inventory (MDASI). It is a measure of symptom burden, which includes symptom severity and how they interfere with daily functioning. For this study, the sub scale is the average of the 5 pre-selected items namely fatigue, pain, disturbed sleep, lack of appetite and drowsiness. This subscale ranges from 0 to 10. The primary outcome is the average of the 70-day area (10 week study) under the curve for the sub scale. AUC ranges from 0 (0*70) to 700 (10*70). To put this into perspective, the average AUC for the placebo group of 200.8 can also be thought of as 2.87 (200.8/70) on a 0 to 10 scale over the 70 day study period. Lower values represent better outcome. Higher values represent worse outcome.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Armodafinil + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Armodafinil orally 150 mg/day + Placebo capsules for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minocycline + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minocycline orally 100 mg twice/day + Placebo capsules for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Armodafinil + Minocycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Armodafinil orally 150 mg/day for 10 weeks + Minocycline orally 100 mg twice/day for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Capsules orally once/day for 10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Armodafinil</intervention_name>
    <description>150 mg by mouth once a day for a 10 week cycle.</description>
    <arm_group_label>Armodafinil + Minocycline</arm_group_label>
    <arm_group_label>Armodafinil + Placebo</arm_group_label>
    <other_name>Nuvigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules taken by mouth once a day for a 10 week cycle.</description>
    <arm_group_label>Armodafinil + Placebo</arm_group_label>
    <arm_group_label>Minocycline + Placebo</arm_group_label>
    <arm_group_label>Placebos</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>100 mg by mouth twice a day for a 10 week cycle.</description>
    <arm_group_label>Armodafinil + Minocycline</arm_group_label>
    <arm_group_label>Minocycline + Placebo</arm_group_label>
    <other_name>Dynacin</other_name>
    <other_name>Minocin</other_name>
    <other_name>Minocin PAC</other_name>
    <other_name>Myrac</other_name>
    <other_name>Solodyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.</description>
    <arm_group_label>Armodafinil + Minocycline</arm_group_label>
    <arm_group_label>Armodafinil + Placebo</arm_group_label>
    <arm_group_label>Minocycline + Placebo</arm_group_label>
    <arm_group_label>Placebos</arm_group_label>
    <other_name>Surveys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a pathologically proven diagnosis of NSCLC and consented to concurrent
             chemoradiation therapy at MD Anderson.

          2. Patients &gt; or =18 years old

          3. Patients who will receive chemoradiation with platinum/taxane-based chemotherapy and
             with a total radiation dose of &gt; 50 Gy, per treating physician's assessment

          4. Patients who speak English or Spanish (due to the novel research and its complexity,
             we are only accruing English or Spanish-speaking patients to the protocol)

          5. Patients must be willing and able to review, understand, and provide written consent
             before starting therapy

        Exclusion Criteria:

          1. Patients who are taking medications or have conditions that potentially preclude use
             of any study medications or interventions, as determined by the treating physician

          2. Patients who are enrolled in other symptom management or treatment clinical trials

          3. Patients currently taking methylphenidate and/or dextroamphetamine.

          4. Patients with a history of clinically significant cutaneous drug reaction, or a
             history of clinically significant hypersensitivity reaction, including multiple
             allergies or drug reaction as documented in the patient medical records

          5. Patients with pre-existing psychosis or bipolar disorder.

          6. Patients with pre-existing renal impairment: The screening cut off for serum
             creatinine &gt;1.5 times upper limits of normal (ULN), according to MD Anderson testing
             standards, will be done by the oncologist to qualify for CXRT.

          7. Patients with pre-existing hepatic impairment: The screening for total bilirubin &gt;1.5
             times ULN will be done by the oncologist to qualify for CXRT. The screening for &gt; 2
             times the upper limit of normal hepatotoxicity, alkaline phosphatase (ALP) and alanine
             aminotransferase (ALT) (and aspartate aminotransferase [AST] if it is ordered and
             available in the medical records) will be done by the oncologist to qualify for CXRT.

          8. Patients with pre-existing Tourette's syndrome.

          9. Patients with hypersensitivity to any tetracyclines.

         10. Patients who are pregnant. Pregnancy will be confirmed by negative urine test. Study
             staff will provide the pregnancy kits to women and make sure the results are known and
             recorded in the follow-up notes in Clinic Station before additional study drug
             prescriptions are filled by the Pharmacy

         11. Patients with uncontrolled cardiac disease, within the past six months history of left
             ventricular hypertrophy, myocardial infarction, and history of mitral valve prolapse
             syndrome with previous central nervous system (CNS) stimulant use.

         12. Patients taking medicines that are strong CYP3A4 inhibitors or inducers (including
             conivaptan, indinavir, nelfinavir, ritonavir, nefazodone, and phenytoin), or strong
             CYP2C19 inhibitors (including citalopram and clopidogrel) .

         13. Patients on vitamin K antagonist warfarin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhongxing Liao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.utmdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 16, 2011</study_first_submitted>
  <study_first_submitted_qc>March 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2011</study_first_posted>
  <results_first_submitted>November 15, 2019</results_first_submitted>
  <results_first_submitted_qc>January 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2020</results_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Symptoms</keyword>
  <keyword>Concurrent Chemoradiation</keyword>
  <keyword>CXRT</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Pain</keyword>
  <keyword>Disturbed Sleep</keyword>
  <keyword>Lack of Appetite</keyword>
  <keyword>Drowsiness</keyword>
  <keyword>Armodafinil</keyword>
  <keyword>Nuvigil</keyword>
  <keyword>Minocycline</keyword>
  <keyword>Dynacin</keyword>
  <keyword>Minocin</keyword>
  <keyword>Minocin PAC</keyword>
  <keyword>Myrac</keyword>
  <keyword>Solodyn</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: July 15, 2011 to October 21, 2013. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Armodafinil</title>
          <description>Armodafinil 150mg (capsule) once a day during entire course of radiation therapy for 10 weeks</description>
        </group>
        <group group_id="P2">
          <title>Minocycline</title>
          <description>Minocycline 100mg (capsule) two times a day during the entire course of radiation therapy for 10 weeks</description>
        </group>
        <group group_id="P3">
          <title>Armodafinil + Minocycline</title>
          <description>Armodafinil orally 150 mg/day for 10 weeks + Minocycline orally 100 mg twice/day for 10 weeks</description>
        </group>
        <group group_id="P4">
          <title>Matching Placebo</title>
          <description>Placebo capsules orally once/day for 10 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of compliance study med</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Armodafinil</title>
          <description>Armodafinil 150mg (capsule) once a day during entire course of radiation therapy for 10 weeks</description>
        </group>
        <group group_id="B2">
          <title>Minocycline</title>
          <description>Minocycline 100mg (capsule) two times a day during the entire course of radiation therapy for 10 weeks</description>
        </group>
        <group group_id="B3">
          <title>Armodafinil+Minocycline</title>
          <description>Armodafinil orally 150 mg/day for 10 weeks + Minocycline orally 100 mg twice/day for 10 weeks</description>
        </group>
        <group group_id="B4">
          <title>Matching Placebo</title>
          <description>Placebo capsules orally once/day for 10 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.67" spread="7.09"/>
                    <measurement group_id="B2" value="60" spread="11.36"/>
                    <measurement group_id="B3" value="66.33" spread="8.08"/>
                    <measurement group_id="B4" value="65" spread="12.77"/>
                    <measurement group_id="B5" value="63.75" spread="8.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Outcome Variable: Combined AUC of Selected Symptoms Fatigue, Pain, Disturbed Sleep, Lack of Appetite and Drowsiness</title>
        <description>Each item is rated on a 0 to 10 scale with 0 = symptom not present or no interference and 10 meaning the symptom severity is as bad as can be imagine or complete interference using the MD Anderson Symptom Inventory (MDASI). It is a measure of symptom burden, which includes symptom severity and how they interfere with daily functioning. For this study, the sub scale is the average of the 5 pre-selected items namely fatigue, pain, disturbed sleep, lack of appetite and drowsiness. This subscale ranges from 0 to 10. The primary outcome is the average of the 70-day area (10 week study) under the curve for the sub scale. AUC ranges from 0 (0*70) to 700 (10*70). To put this into perspective, the average AUC for the placebo group of 200.8 can also be thought of as 2.87 (200.8/70) on a 0 to 10 scale over the 70 day study period. Lower values represent better outcome. Higher values represent worse outcome.</description>
        <time_frame>During 10 weeks of CXRT</time_frame>
        <population>Of the 14 randomized patients, 12 (85% were evaluable for the primary efficacy analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Armodafinil</title>
            <description>Armodafinil 150mg (capsule) once a day during entire course of radiation therapy (10 weeks + 2 days</description>
          </group>
          <group group_id="O2">
            <title>Minocycline</title>
            <description>Minocycline 100mg (capsule) two times a day during the entire course of radiation therapy (10 weeks + 2 days)</description>
          </group>
          <group group_id="O3">
            <title>Armodafinil+Minocycline</title>
            <description>Armodafinil orally 150 mg/day for 10 weeks + Minocycline orally 100 mg twice/day for 10 weeks</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo</title>
            <description>Placebo Capsules orally once/day for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Outcome Variable: Combined AUC of Selected Symptoms Fatigue, Pain, Disturbed Sleep, Lack of Appetite and Drowsiness</title>
          <description>Each item is rated on a 0 to 10 scale with 0 = symptom not present or no interference and 10 meaning the symptom severity is as bad as can be imagine or complete interference using the MD Anderson Symptom Inventory (MDASI). It is a measure of symptom burden, which includes symptom severity and how they interfere with daily functioning. For this study, the sub scale is the average of the 5 pre-selected items namely fatigue, pain, disturbed sleep, lack of appetite and drowsiness. This subscale ranges from 0 to 10. The primary outcome is the average of the 70-day area (10 week study) under the curve for the sub scale. AUC ranges from 0 (0*70) to 700 (10*70). To put this into perspective, the average AUC for the placebo group of 200.8 can also be thought of as 2.87 (200.8/70) on a 0 to 10 scale over the 70 day study period. Lower values represent better outcome. Higher values represent worse outcome.</description>
          <population>Of the 14 randomized patients, 12 (85% were evaluable for the primary efficacy analysis).</population>
          <units>Units on a scale week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.4" spread="181.4"/>
                    <measurement group_id="O2" value="81.1" spread="22.2"/>
                    <measurement group_id="O3" value="255.9" spread="65.3"/>
                    <measurement group_id="O4" value="200.8" spread="106.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259.3" spread="168.5"/>
                    <measurement group_id="O2" value="127.2" spread="60.5"/>
                    <measurement group_id="O3" value="372" spread="113.5"/>
                    <measurement group_id="O4" value="279.8" spread="193.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.8" spread="233.6"/>
                    <measurement group_id="O2" value="114.5" spread="135.6"/>
                    <measurement group_id="O3" value="185.3" spread="121."/>
                    <measurement group_id="O4" value="190" spread="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disturbed Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.2" spread="165"/>
                    <measurement group_id="O2" value="80" spread="44.3"/>
                    <measurement group_id="O3" value="213.2" spread="81.5"/>
                    <measurement group_id="O4" value="224.7" spread="205.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lack of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.3" spread="134.6"/>
                    <measurement group_id="O2" value="27.7" spread="28.1"/>
                    <measurement group_id="O3" value="298.3" spread="23.3"/>
                    <measurement group_id="O4" value="189" spread="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.3" spread="209.7"/>
                    <measurement group_id="O2" value="59.2" spread="32.8"/>
                    <measurement group_id="O3" value="210.7" spread="82.3"/>
                    <measurement group_id="O4" value="120.3" spread="69.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 16 weeks</time_frame>
      <desc>All participants will be seen weekly in the radiation oncology clinics, allowing clinic and research staff to closely monitor potential adverse events during treatment. Participants will continue their symptom interventions for an additional 3 weeks after therapy is completed (when study treatment-related symptoms are at their peak)</desc>
      <group_list>
        <group group_id="E1">
          <title>Armodafinil + Placebo</title>
          <description>Armodafinil orally 150 mg/day + Placebo capsules for 10 weeks</description>
        </group>
        <group group_id="E2">
          <title>Minocycline + Placebo</title>
          <description>Minocycline orally 100 mg twice/day + Placebo capsules for 10 weeks</description>
        </group>
        <group group_id="E3">
          <title>Armodafinil + Minocycline</title>
          <description>Armodafinil orally 150 mg/day for 10 weeks + Minocycline orally 100 mg twice/day for 10 weeks</description>
        </group>
        <group group_id="E4">
          <title>Placebos</title>
          <description>Placebo Capsules orally once/day for 10 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Zhongxing Liao, MD/Professor, Radiation Oncology Department</name_or_title>
      <organization>MD Anderson Cancer Center</organization>
      <phone>713-563-2300</phone>
      <email>zliao@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

